ReviewNature reviews. Nephrology2026
Anti-neutrophil cytoplasmic antibody-associated vasculitis: biological insights and biomarker-guided disease management.
Review in Nature reviews. Nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Earlier recognition of anti-neutrophil cytoplasmic antibody-associated vasculitis has led to more timely treatment initiation and improvements in patient survival, despite limited available therapeutic options. Current drugs can induce remission in most patients, but therapies are not individualized, with consequent over-treatment of some patients and under-treatment of others, leading to considerable morbidity from both disease and therapy. Diverse research strategies, from large clinical datasets to single-cell molecular analyses, have improved understanding of antibody-associated vasculitis biology substantially, with implications for patient management. Longitudinal data from registries and trial databases have highlighted variations in the patterns and progression of kidney disease. Efforts to improve current biological readouts of disease activity have tried to identify more dynamic and clinically applicable biomarkers to inform, in real time, the level of therapy required. Examples of such readouts include urinary levels of CD163 and CC-chemokine ligand 2, urinary T cell numbers and serum levels of various immune biomarkers, although further validation studies are required. Several important questions - how to prevent kidney disease progression, predict relapse and determine immunological quiescence to inform duration of therapy - remain incompletely answered. Here, we highlight some of the latest research advances that can help to inform clinicians about the biology of disease and might ultimately enable customization of treatment.
Indexed as
Identifiers
42120751What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.